CD8A and neoplasm: Growing evidence suggests that for a better clinical response to immunotherapies, the accumulation of CD8+ T cells in the stroma is not sufficient and the inability of CD8+ T cells to reach and contact tumor cells is an important mechanism of resistance to cancer immunotherapy [24,30,37].